A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients with Advanced or Recurrent Solid Tumors
NCT #
NCT04196257
Condition(s)
Endometrial Cancer, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Solid Tumor
Molecular Target(s)
Grb2
Drug Classification(s)
Small Molecule
Agents(s)
BP1001
Phase(s)
I
Mechanism of Action
BP1001 a liposome-incorporated Grb2 antisense oligodeoxynucleotide binds directly to and blocks Grb2 mRNA, thereby preventing Grb2 protein synthesis, leading to inhibition of cell proliferation of cancer cells overexpressing Grb2.
Purpose
- How much of the study agent can be given with an acceptable level of side effects
- The effects of the study agent (good and bad)
- How much of the study agent is absorbed into the blood and how fast it is removed
- If research tests can be used in the future to predict who will benefit from BP1001A
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.